Current stock page

Stock Analysis

Krystal Biotech, Inc. (KRYS) Stock Analysis

Krystal Biotech, Inc. (KRYS) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

KRYS Stock Analysis Summary

Krystal Biotech, Inc. (KRYS) currently has an AIQ Score of 69/100, indicating a bullish setup. Quality is the strongest factor at 83/100. Momentum is the weakest current factor at 58/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

KRYS at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$305.23
AIQ Score69/100
Overall ViewBullish
Technical Analysis ConsensusStrong Sell
Market Cap$9.04B
P/E Ratio (TTM)39.85
Forward P/E—
EPS (Q3 FY2026)$2.13
Revenue (Q3 FY2026)$127.34M
Dividend Yield (TTM)0.00%
Beta0.74
Volume110.29K
52-week range$198.02-$382.54
RSI 1443.03
50-Day SMA$326.77
200-Day SMA$309.71
Analyst Price Target$428.50
Next EarningsFeb 16, 2027
As of Nov 13, 2026 · Market close

KRYSKrystal Biotech, Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 8/10
$305.23−$0.45 (−0.15%)

Latest quote

  • Momentum
    58
  • Value
    67
  • Quality
    83
  • Risk resilience
    69
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

KRYS Stock Analysis Summary

Krystal Biotech, Inc. (KRYS) currently has an AIQ Score of 69/100, indicating a bullish setup. Quality is the strongest factor at 83/100. Momentum is the weakest current factor at 58/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, KRYS has AIQ Score of 69/100 with Quality base of 83/100 and fading Momentum at 58/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Quality (83/100) leads while Momentum (58/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -0.15% stock move · KRYS classified in Biotechnology.

Current Evidence

BullishKRYS is in a bullish AIQ regime; Quality is the strongest visible factor at 83/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is KRYS Bullish or Bearish Right Now?

KRYS currently has a bullish overall setup. Quality is the strongest factor at 83/100, while Momentum is weakest at 58/100. The current evidence suggests a constructive setup.

Bull Case
  • - Quality is supportive at 83/100.
  • - Risk Resilience is supportive at 69/100.
  • - Analyst target implies +40.39% upside from the latest quote.
Bear Case
  • - Price is -1.45% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (33 vs 4).

Current Consensus

KRYS's Technical Analysis Consensus is currently Strong Sell, with 4 buy, 9 neutral, and 33 sell votes. KRYS's 14-day RSI is 43.03, which places the stock in a weaker momentum range. KRYS's beta is 0.74, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in KRYS?

The largest recent change in KRYS is Momentum moving down by 8.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.

AIQ Score
-3.0
Momentum
-8.0
Quality
+0.0
Risk
+0.0

What Would Change the KRYS Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

KRYS Decision Framework

Public evidence layers, setup checks, and risk context for Krystal Biotech, Inc..

Krystal Biotech, Inc. (KRYS) Stock Analysis

Krystal Biotech, Inc. has an AIQ Score of 69/100 in a Bullish regime. Quality is strongest at 83/100. Beta is 0.74, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextKRYS is in a Bullish AIQ regime with score 69/100.
Signal ConflictThe primary conflict is that quality leads at 83/100 while momentum lags at 58/100.
Factor EvidenceMomentum 58/100 · Value 67/100 · Quality 83/100 · Risk 69/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Quality is the strongest factor at 83/100.

TimingWait

Momentum is 58/100 and RSI (14) is 43.0.

Regime fitPass

KRYS is in a Bullish regime at 69/100.

Risk controlPass

Risk factor is 69/100 with beta 0.74 and annual volatility 39.38%.

ConflictWait

Current conflict: quality leads at 83/100 while momentum lags at 58/100.

AIQ Score
69/100
Price
$305.23
Beta
0.74
RSI (14)
43

KRYS Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

KRYS Fundamentals

KRYS valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$127.34M
Net income
$63.07M
Free cash flow
$90.25M
View full KRYS fundamental analysis

KRYS Technical Analysis

KRYS technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
43.03
Price vs SMA-50
-6.59%
View full KRYS technical analysis

KRYS Stock Catalysts

Track KRYS earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 16, 2027
Analyst target
$428.50
News items
4
View KRYS earnings and stock catalysts

KRYS Dividend Analysis

KRYS dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View KRYS dividend history and analysis

KRYS Financial Data

KRYS revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$127.34M
EPS
$2.13
Periods
8
View KRYS financials

KRYS Risk Analysis

KRYS volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.74
Risk score
69/100
1Y volatility
39.38%
View KRYS risk analysis

KRYS Stock News

KRYS stock news, market tone, recent headlines, and catalyst context.

News items
4
Updated
Nov 15, 2026
Sentiment
—
Read KRYS stock news

KRYS vs Biotechnology Peers

Current peer cohort: KRYS · KURA · KYMR · LGND · MAZE. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
KRYS
Current stock
69/10067/10058/10069/1001.1639.38%Current
KURA
Kura Oncology, Inc.
47/10070/10040/10039/100-0.2563.01%KRYS vs KURA
KYMR
Kymera Therapeutics, Inc.
65/10043/10087/10060/1001.3363.12%KRYS vs KYMR
LGND
Ligand Pharmaceuticals Incorporated
76/10061/10086/10070/1001.2536.55%KRYS vs LGND
MAZE
Maze Therapeutics, Inc.
59/10042/10083/10047/1000.4167.20%KRYS vs MAZE
Pairwise Compare links: KURA · KYMR · LGND · MAZEKRYS vs KURAKRYS vs KYMRKRYS vs LGNDKRYS vs MAZECompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a KRYS stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for KRYS: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
39.85
As of Nov 13, 2026
Revenue growth
30.21%
Gross margin
93.36%
Current debt / equity
0.01
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$127.34M
Quarter net income
$63.07M
Quarter free cash flow
$90.25M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Mixed
RSI 14
43.03
MACD
-6.52

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
69/100
Beta
0.74
Annual volatility
39.38%
Max drawdown
-21.75%

KRYS Stock FAQ

What is KRYS stock price today?

Krystal Biotech, Inc.'s current stock price is $305.23. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is KRYS bullish or bearish right now?

KRYS's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is KRYS's market cap?

KRYS's market cap is $9.04B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is KRYS's current P/E ratio?

KRYS's current P/E ratio is 39.85 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is KRYS's RSI?

KRYS's 14-day RSI is 43.03 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is KRYS above its 50-day and 200-day moving averages?

KRYS is -6.59% from its 50-day SMA and -1.45% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is KRYS's next earnings date?

KRYS's next earnings date is currently listed as Feb 16, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does KRYS pay a dividend?

KRYS's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.